In patients with T2DM, DPP4is reduce the degradation incretin hormones, hence increasing their half-life and promoting their actions (insulin secretion, decrease of gastric emptying rate, and inhibition of glucagon secretion). The gene discussed is GCG; the disease is type 2 diabetes mellitus.